MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

By sjmartinez • November 10, 2023

Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392. PMID: 37945286.

Tags: Ankylosing, Antirheumatic Agents, Arthritis, Psoriatic, Publications, Rheumatoid, Rheumatology, Spondylitis

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma

Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Couselo EM, Burris HA 3rd, Postow MA, Chmielowski B, Middleton[...]

Lem3, a phospholipid flippase subunit, influences Candida albicans pathogenicity through maintenance of plasma membrane asymmetry

Agrawal P, Kumar P, Ali B, Nabeela S, Ikeh MAC, Morschhäuser J, Andes DR, Nobile CJ, Prasad R, Uppuluri P, Panwar SL. Lem3, a phospholipid[...]

Omitting Radioactive Iodine after Therapeutic Lateral Neck Dissection May Be the Next Step in De-Escalating Initial Treatment of Papillary Thyroid Cancer

Yeh MW. Omitting Radioactive Iodine after Therapeutic Lateral Neck Dissection May Be the Next Step in De-Escalating Initial Treatment of Papillary Thyroid Cancer. Thyroid. 2026[...]